- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02476513
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
Study Overview
Status
Conditions
Detailed Description
Patients with elevated central adiposity have an increased risk of esophageal disorders; we will correlate central adiposity with advanced esophageal pathologies (BE and EAC). This will be done by comparing body mass and fat distribution to tissue abnormalities found by pathology review of EGD biopsy. It is anticipated that the group of men in this study will have an increased likelihood of histopathologic alteration, which we will fit into our scale (0-no inflammation, 1-inflammation or BE, 2-BE with dysplasia, and 3-carcinoma) according to the referral pattern at UAB's outpatient gastroenterology clinic.
At the molecular level, there is also a relationship between pro-inflammatory cytokines and obesity, which may contribute to esophageal disorder [28]. Metabolically active fat cells secrete cytokines exclusive to adipose tissue (adipokines, leptin/adiponectin) as well as the more classic signaling molecules, tumor necrosis factor alpha (TNF-α); interleukins (IL)-1, IL-6, IL-8, and IL-10; monocyte chemoattractant protein 1 (MCP-1); and macrophage inflammatory protein 1 (MIP 1) [29-33]. Obesity-triggered pro-inflammatory molecules may promote tissue injury, leading to metaplasia and dysplasia in BE and, subsequently, to carcinoma.
Thus, by measuring these pro-inflammatory markers in our prospective patient population, it will be determined if patients with elevated levels exhibit pathologic disorders in the esophagus and if the differential expression of these molecular markers correlates with degree of esophageal disorder. We will analyze samples collected from men for adipocytokines and for inflammatory mediators that are released with tissue injury. Additionally, we will examine molecular markers that correlate with more advanced esophageal disorders (BE with high grade dysplasia and EAC).
Persistent stimulation is needed to cause stepwise progression from the early stages of esophageal injury, to BE, to carcinoma. Since the molecular events that lead to this transformation are not known, our goal is to profile biopsy tissues collected from the prospective cohort of 60 men, analyzed by IHC for p53, Ki67, cyclin D1, IL-6, IL-8, Cox-2, DKK-1, CD44, leptin, and adiponectin. These molecules are known to be involved in transformation of normal esophageal epithelium to EACs via progression from metaplasia and BE to low-grade dysplasia and high-grade dysplasia. [34]. The clinical outcome measurements will be correlated with the levels of these molecules, determined by IHC, with metaplasia, degree of dysplasia in BE, and stage of EAC. For BE tissues, there is a correlation between the extent of p53 staining and aggressive clinical features. Our preliminary findings on six BEs, selected from the patient population at UAB, indicate that a high proportion of p53 staining directly correlates with high-grade lesions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men only who are referred for upper endoscopy for the first time.Or who have had normal upper endoscopy in the last 10 years
- Age criteria: 25-75 years in age
- Patients undergoing EGD and willing to also consent to tissue biopsy, blood work and CT scan.
- ECOG PFS 0-1
Exclusion Criteria:
- Unstable medical condition, such as uncontrolled diabetes mellitus or hypertension or active infections requiring systemic therapy
- Clinical evidence of cardiac or pulmonary dysfunction including, but not limited to, unstable congestive heart failure, uncontrolled arrhythmias, unstable coagulation disorders, or recent myocardial infarction (within 6 months)
- Documented history of erosive esophagitis or non-erosive esophageal luminal. No prior history of Barrett's esophagus.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of obesity and increase risk of esophageal adenocarcinomas
Time Frame: 1-2 years
|
We will use data collected from the waist measurements and the measurement compiled from the CT scan of the abdomen.
The correlate it with the actual tissue markers(if any) found from the pathologists review.
|
1-2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Developing a group of tissue markers that specifically relates to a increase in esophageal cancer
Time Frame: 1-2 years
|
The pathologist and bio-marker laboratory will use the blood samples and tissue to provide a assay that can be used later to provide insight into the increase risk of developing Barrett's esophagus or esophageal adenocarcinoma
|
1-2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: James A Posey, M.D., University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UAB 1354
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Diseases
-
Johns Hopkins UniversityWithdrawnEsophageal Perforation | Esophageal Fistula | Esophageal Strictures | Esophageal Leak | Endostitch | Esophageal StentUnited States
-
Federal University of São PauloUnknownEsophageal Stricture | Caustic Esophageal Stricture | Peptic Esophageal Stricture | Post-Surgical Esophageal StrictureBrazil
-
Istituto Clinico HumanitasRecruiting
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
Mayo ClinicRecruitingOpioid-Induced Esophageal DysfunctionUnited States
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... and other collaboratorsCompleted
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
Mayo ClinicCompletedEsophageal Dilation | Refractory Benign Esophageal StrictureUnited States
-
Mayo ClinicTerminatedAchalasia | Esophageal Achalasia | Achalasia, EsophagealUnited States
-
Zagazig UniversityCompletedIatrogenic Esophageal PerforationEgypt